Advertisement
  • What Older Patients Value

    Many older adults with cancer place more importance on maintaining their independence and cognitive abilities than on living as long as possible.

    by Cheryl Platzman Weinstock

  • Omitting Obesity

    Many cancer clinical trials do not track what proportion of enrolled patients are obese, a study finds. These patients may be underrepresented in research.

    by Cici Zhang

  • Measuring Your Movement

    Researchers are exploring whether wearable personal activity monitors could provide doctors with a more complete picture of cancer patients’ well-being.

    by Brad Jones

  • Men Less Likely to Get Genetic Testing

    A study suggests women are more likely than men to undergo genetic testing for mutations linked to hereditary cancer.

    by Cheryl Platzman Weinstock

  • The Ins and Outs of Tumor Testing

    In a session at the AACR Annual Meeting, oncologists discussed the state of cancer precision medicine—and engaged with patient advocates.

    by Kate Yandell

  • A Response to Roadblocks

    The Biden Cancer Initiative Colloquium gathered experts to discuss obstacles preventing access to care at the AACR Annual Meeting.

    by Kevin McLaughlin

  • Artificial Intelligence Characterizes Cancer

    At the AACR Annual Meeting 2018, researchers at Google compared the speed and accuracy of human pathologists and computer algorithms in diagnosing and grading cancer.

    by Kevin McLaughlin

  • A New Type of Drug Approval

    At the AACR Annual Meeting, researchers and regulators discuss what it means to tie approval of an immunotherapy to tumors’ molecular characteristics, not to their tissues of origin.

    by Kate Yandell

  • Non–Small Cell Lung Cancer Takes Center Stage

    A trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non–small cell lung cancer treatment.

    by Brad Jones

  • Pembrolizumab Shows Further Promise for Melanoma

    In a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.

    by Brad Jones

Advertisement

From the AACR

Advertisement

Video

The Financial Toll of Cancer

Advertisement

social media

donate to the AACR